Shareholder alert: weisslaw llp reminds adms, flxn, azpn, and ebmt shareholders about its ongoing investigations

New york, oct. 26, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com adamas pharmaceuticals, inc. (nasdaq: adms) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of adamas pharmaceuticals, inc. (nasdaq: adms) in connection with the proposed acquisition of the company by supernus pharmaceuticals, inc.  under the terms of the agreement, adms shareholders will receive $8.10 per share in cash, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of adms's lead product, gocovri, for each share of adms stock that they hold.
ADMS Ratings Summary
ADMS Quant Ranking